Another important aspect of granulocyte transfusions is their use in patients with chronic granulomatous disease (CGD) undergoing hematopoietic cell transplantation (HCT) or gene therapy.

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

"This study highlights the potential for the gene therapy field to provide effective long-term therapies for chronic conditions, which currently require frequent treatments with painful and/or ...

The FDA cleared Prime Medicine’s investigational new drug (IND) application for PM359 for the treatment of chronic granulomatous ... field of next-generation gene editing.

Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.